# Agentic Pre-Market Brief — 2026-11-02 (Monday)

- **Scheduled fire:** 2026-11-02 08:30 ET (`scheduled_at_ms` 1793626200000) — on time, not a replay.
- **Generated:** 2026-11-02 08:41 EST
- **Market open:** 09:30 ET. Cash open in ~48 min at time of writing.
- **Scope:** entire US-listed equity universe (no watchlist scoping). Pre-market prints from the TradingView public screener; regular-session closes cross-checked against the MCP-bridge `market-recap` (Yahoo-sourced).

---

## 1. TL;DR — five themes, clustered

1. **Marvell buys Lumentum — $115B all-stock, and the market is selling both legs.** MRVL is -3.3% at $190.00 and LITE -5.1% at $797.84 pre-market, *after* an initial pop to +3.9% on the announcement. A fixed 4.500 exchange ratio means LITE's value is now hostage to MRVL's: the implied value is 4.500 x $190.00 = **$855** vs LITE's $797.84 print — a **-6.7%** discount to deal value. Friday had already cost MRVL -10.0% and LITE -8.6%.
2. **AI-capex credit stress, not AI-demand collapse.** Futures are green (ES +0.30%, NQ +0.57%) while ORCL sits -2.9% at $126.89 after -6.4% on Friday. Oracle's 5y CDS is near a record ~300bp and S&P has it one notch above junk — the market is repricing *financing*, not demand. Friday's spark was Intel's collapse (-28.6%).
3. **FDA binary biotech — the biggest single movers on the board.** INO +263.5% to $2.19 on FDA accelerated approval of Voceryq (first FDA-approved DNA medicine); PGEN -28.0% is the direct loser; DRUG -45.8% on a partial clinical hold; KPTI -64.6% on a Chapter 11 filing.
4. **Event-driven M&A/ownership moves.** EVGO +44.4% to $1.82 after LS Power agreed to take it private at $2.00/share cash — still **-9.0%** below the deal price. PERI +31.3% to $11.42 on a 6-K.
5. **Post-earnings dispersion is brutal.** NSSC -18.2%, KOS -8.4%, CHKP -6.0% vs IDXX +7.8%, TEM +3.9% — the full spread of reactions to a single morning's prints.

**Tape breadth:** 81 names up ≥3% pre-market and 48 down ≤-3%, screened for a tradeable pre-market tape (≥100k shares, or ≥$200M cap with ≥10k shares). This is **not a thin tape** — there are more than enough themes; the risk today is concentration, not absence of signal.

**Watchlist:** the user's personal watchlist file (`research/watchlist.yaml`) exists only on the local Windows host and is **not reachable from the Cloud sandbox** — no watchlist section is published today. See §6 and Source health.

---

## 2. Theme clusters

### Cluster A — AI connectivity M&A: Marvell/Lumentum ($115B)

**Leader (by magnitude):** MRVL -3.3% / LITE -5.1% — the deal itself is the driver.

| Ticker | Fri close | Fri % | Pre-market | Pre % | pm vol | %ADV |
|---|---|---|---|---|---|---|
| MRVL | 196.40 | -10.0% | $190.00 | -3.3% | 1,482,451 | 7.2% |
| LITE | 840.70 | -8.6% | $797.84 | -5.1% | 373,926 | 7.4% |
| COHR | 210.32 | -11.3% | $216.59 | +3.0% | 694,468 | 9.5% |
| AAOI | 69.05 | -12.8% | $69.89 | +1.2% | 709,968 | 6.6% |
| POET | 5.20 | -8.1% | $5.28 | +1.5% | 250,132 | 3.0% |

- **The deal:** Marvell acquires Lumentum in an all-stock transaction, enterprise value **$115B**, implied value **~$1,132 per LITE share**, a **23.9% premium** to Oct-28 unaffected closes. LITE holders receive **4.500 MRVL per share**; post-closing ownership **67% MRVL / 33% LITE**. Boards approved unanimously; close expected **H1 2028**; management guides to **>$1B annual run-rate cost synergies** and year-one non-GAAP EPS accretion.
- **Why both legs are down:** a *fixed* exchange ratio transfers value between the two stocks. With MRVL at $190.00 (it closed Friday at 196.40), the implied LITE value is $855; LITE at $797.84 is **-6.7%** to that. StockTwits' own thesis flags the same mechanic: LITE holders are frustrated the stock is falling *despite* the headline premium because the payoff is MRVL's share price.
- **Read-through:** the rest of the optical/AI-connectivity complex is *not* following LITE down — COHR +3.0%, AAOI +1.2%, POET +1.5% are all positive pre-market after Friday's rout (COHR -11.3%, AAOI -12.8%, POET -8.1%). The market is treating this as a deal-specific dilution/exchange-ratio story, not a sector de-rating.
- **Not corroborated as a catalyst:** no separate news today for POET's Foxconn photonics claim beyond the third-party report in the StockTwits thesis.

### Cluster B — AI-infrastructure financing: Oracle, and the debt-funding question

**Leader:** ORCL -2.9% at $126.89, on -6.4% Friday.

| Ticker | Fri close | Fri % | Pre-market | Pre % | %ADV |
|---|---|---|---|---|---|
| ORCL | 130.67 | -6.4% | $126.89 | -2.9% | 2.7% |
| CRWV | 54.87 | -9.7% | $56.08 | +2.2% | 1.9% |
| IREN | 23.95 | -8.8% | $24.14 | +0.8% | 1.6% |
| WULF | 11.73 | -8.0% | $12.07 | +2.9% | 2.6% |
| INTC | 65.76 | -28.6% | $65.16 | -0.9% | 3.2% |
| NVDA | 204.64 | -4.2% | $206.52 | +0.9% | 1.1% |

- **The mechanism:** investors are repricing how AI data-center buildouts get *financed*, not whether they get built. Oracle carries **$118B of long-term debt**; analysts model free cash flow at **-$23.7B in 2026** and **-$36B in 2027**. Its 5-year CDS was approaching a **record ~300bp** on Thursday, and S&P has it **one notch above junk**. ORCL's Nov-2032 notes were yielding 7.24%.
- **Friday's spark:** Intel fell **28.58%** — its worst day since 1974, >$140B of market value — on a Q4 guide ($15-16B vs ~$17.07B expected) and $0.25 adj EPS vs $0.43 expected, with no positive free cash flow expected in 2027. Amazon's cash-flow/capex disclosure compounded it. The Nasdaq fell 2.86%, the S&P 1.82% (its worst day since June), the SOX index 7.2%.
- **Today's read:** the AI complex is *bouncing* — CRWV, IREN, WULF, NVDA, COHR all green pre-market, and INTC is only -0.9% — while ORCL stays weak. The market is separating 'AI capex beneficiary' from 'AI capex *borrower*'.

### Cluster C — FDA/regulatory biotech (the day's largest single moves)

| Ticker | Fri close | Pre-market | Pre % | pm vol | %ADV | Catalyst |
|---|---|---|---|---|---|---|
| INO | 0.60 | $2.19 | +263.5% | 38,319,358 | 594.9% | FDA accelerated approval — Voceryq, RRP |
| PGEN | 6.94 | $5.00 | -28.0% | 819,259 | 16.0% | Inovio's approval pressures PAPZIMEOS |
| DRUG | 54.98 | $29.78 | -45.8% | 11,109 | 8.3% | FDA partial clinical hold, BMB-101 IND |
| KPTI | 0.66 | $0.23 | -64.6% | 3,188,084 | 86.7% | Chapter 11 + Ayrmid merger agreement |

- **INO +263.5%:** the FDA granted accelerated approval to **Voceryq** (doruxapapogene ralaplasmid) to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. In the RRP-001 trial, **7 of 26** efficacy patients (27%) had no surgical excision over 12 months. It is the **first FDA-approved DNA medicine**. Shipping in ~60 days, full launch expected Q1 2027; a confirmatory protocol is due to the FDA by end-2026. INO held an 8:00 AM ET call today.
- **PGEN -28.0% is the mirror image, not an independent story:** Precigen's PAPZIMEOS competes directly with Voceryq in the same indication, and the market is repricing its commercial position (it was +4.5% on Friday).
- **DRUG -45.8%:** the FDA placed the IND for BMB-101 in developmental/epileptic encephalopathies (Protocol BMB-101-105) on a **partial clinical hold** — cited reasons are toxicity in mice and inadequate PK and juvenile-toxicity data for pediatric enrollment. The company says the mouse findings were incidental; the full hold letter is due within 30 days. Other trials are unaffected.
- **KPTI -64.6%:** Karyopharm filed **Chapter 11** in the Southern District of Texas, with a Restructuring Support Agreement to merge with **Ayrmid Ltd.** as lead bidder in a court-supervised sale, backed by up to **$55M DIP financing**. Expected to close Q1 2027. It also reports Q3 after the close today.

### Cluster D — Event-driven ownership changes

- **EVGO +44.4% to $1.82 (pre-market volume 19,871,064, 617% of ADV):** **LS Power Equity Advisors agreed to acquire EVgo for $2.00 per share in cash** (reported 07:43 ET). LS Power already holds ~178M EVGO shares, ~56% of the voting stock. At $1.82 the stock is **-9.0%** to the deal price, versus a +58.7% headline move from Friday's $1.26. EVgo's own Q3 is not until Nov 9 — this is a pure M&A repricing.
- **PERI +31.3% to $11.42 (285% of ADV):** Perion Network filed a **6-K foreign issuer report** today (material corporate disclosure). The move is a 20-32x relative-volume print; the 6-K's substance was not readable from the sources reached, so no catalyst claim is made beyond the filing itself.
- **CLRO +75.4% to $5.98 (112% of ADV):** **no fresh fundamental news** — this is a low-float momentum run (~2.68M shares outstanding) that carried the stock from sub-$2 to above $6 in a week before it closed Friday at $3.41. Fundamentals remain poor (Q2 net loss ~$914K, negative equity). Labelled *single-name idiosyncratic*; treat as a chart, not a story.

### Cluster E — Post-earnings dispersion + guidance

| Ticker | Fri close | Pre-market | Pre % | Reported vs est. |
|---|---|---|---|---|
| IDXX | 551.21 | $594.00 | +7.8% | EPS $4.01 vs $3.71 est; rev $1.21B vs $1.19B est |
| TEM | 72.22 | $75.02 | +3.9% | EPS $0.07 vs -$0.09 est; rev $411.5M vs $409.5M est |
| AXSM | 144.43 | $139.00 | -3.8% | EPS -$0.25 vs -$0.65 est; rev $259.7M vs $249.4M est |
| KOS | 2.85 | $2.61 | -8.4% | EPS $0.06 vs $0.13 est; rev $409.9M vs $455.3M est |
| NSSC | 39.35 | $32.20 | -18.2% | EPS $0.34 vs $0.38 est; rev $50.0M vs $52.1M est |
| CHKP | 152.11 | $143.00 | -6.0% | reported pre-market; rev $669.8M vs $672.1M est |

- **AXSM is the instructive one:** a clear beat on both lines and the stock is *down* pre-market — the market is trading the absence of quantified guidance and elevated opex, not the print.
- **FLNC -5.5% to $5.41 (10% of ADV):** repeated FY2026 guidance cut, attributed mainly to Houston manufacturing delays holding up deliveries; management execution is the focus.
- **TGTX** sits at a 52-week high into its Q3 print (StockTwits thesis; no confirmed report date found), +1.3% pre-market on thin volume (14,645 shares) — not a tradeable print.

---

## 3. Pre-market gaps — top 25 market-wide

Universe: all US-listed `type=stock` on TradingView (REITs and ADRs included — no common-stock re-filter, no domicile filter). Filter: pre-market volume ≥100k shares, **or** market cap ≥$200M with ≥10k pre-market shares — so a ±20% print on 100 shares cannot enter the table. Read the `%ADV` column: anything under ~5% is a thin tape, not a market. `close` is the Fri 2026-10-30 regular-session close; pre-market change is versus that close.

| Ticker | Name | Pre % | Pre px | Fri close | pm vol | %ADV | Mcap $M | Sector |
|---|---|---|---|---|---|---|---|---|
| INO | Inovio Pharmaceuticals, In | +263.5% | 2.19 | 0.60 | 38,319,358 | 594.9% | 62 | Health Technology |
| CLRO | ClearOne, Inc. | +75.4% | 5.98 | 3.41 | 6,930,686 | 111.6% | 9 | Consumer Durables |
| EVGO | EVgo Inc. | +44.4% | 1.82 | 1.26 | 19,871,064 | 617.4% | 396 | Retail Trade |
| PERI | Perion Network Ltd | +31.3% | 11.42 | 8.70 | 641,587 | 284.9% | 342 | Technology Services |
| INLF | INLIF LIMITED | +24.7% | 0.23 | 0.18 | 70,151,197 | 519.3% | 0 | Producer Manufacturing |
| TOVX | Theriva Biologics, Inc. | +17.9% | 0.20 | 0.17 | 46,933,491 | 9104.5% | 8 | Health Technology |
| XXII | 22nd Century Group, Inc | +16.7% | 0.08 | 0.07 | 137,992,500 | 570.0% | 1 | Health Technology |
| ELAB | PMGC Holdings Inc. | +8.4% | 2.82 | 2.60 | 8,130,425 | 23428.9% | 2 | Health Technology |
| PSQL | Pasqal Holding SA | +8.0% | 5.65 | 5.23 | 10,443 | 1.5% | 1,110 | Electronic Technology |
| IDXX | IDEXX Laboratories, Inc. | +7.8% | 594.00 | 551.21 | 18,855 | 3.7% | 43,425 | Health Technology |
| BRAI | Braiin Limited | +7.8% | 2.64 | 2.45 | 516,195 | 12.7% | 505 | Technology Services |
| AVR | Anteris Technologies Globa | +7.6% | 6.79 | 6.31 | 39,974 | 2.9% | 615 | Health Technology |
| XMAX | XMAX, Inc. | +7.4% | 6.89 | 6.42 | 71,715 | 9.5% | 416 | Consumer Durables |
| CAPR | Capricor Therapeutics, Inc | +6.9% | 6.82 | 6.38 | 62,617 | 1.9% | 371 | Health Technology |
| TATT | TAT Technologies Ltd. | +6.8% | 33.95 | 31.80 | 24,547 | 20.8% | 413 | Electronic Technology |
| CJMB | Callan JMB Inc. | +6.6% | 0.45 | 0.42 | 366,863 | 6.7% | 2 | Transportation |
| GPUS | Hyperscale Data, Inc. | +6.2% | 0.17 | 0.16 | 2,984,321 | 6.3% | 31 | Producer Manufacturing |
| NCPL | Netcapital Inc. | +5.7% | 1.68 | 1.59 | 458,231 | 2.4% | 12 | Commercial Services |
| QURE | uniQure N.V. | +4.8% | 26.02 | 24.83 | 423,184 | 14.4% | 1,722 | Health Technology |
| BTBT | Bit Digital, Inc. | +4.6% | 0.84 | 0.80 | 128,036 | 0.5% | 289 | Commercial Services |
| CABA | Cabaletta Bio, Inc. | +4.4% | 1.58 | 1.51 | 15,964 | 0.3% | 256 | Health Technology |
| GEO | Geo Group Inc (The) REIT | +4.3% | 29.75 | 28.52 | 25,153 | 1.0% | 3,754 | Commercial Services |
| ALLO | Allogene Therapeutics, Inc | +4.2% | 1.23 | 1.18 | 12,294 | 0.2% | 408 | Health Technology |
| SLGB | Smart Logistics Global Lim | +4.2% | 0.32 | 0.31 | 17,946,622 | 130.6% | 13 | Transportation |
| ECHO | EchoStar Corporation | +4.2% | 101.00 | 96.94 | 152,632 | 3.8% | 28,192 | Communications |

_Screen totals: 81 qualifying gainers ≥3%; 48 qualifying losers ≤-3%. The complete 427-name screen (every ≥3% / ≤-3% name, before the liquidity screen) ships alongside this brief as `2026-11-02-pre-market.csv`._

## 4. Top losers — top 10 market-wide

| Ticker | Name | Pre % | Pre px | Fri close | pm vol | %ADV | Mcap $M | Sector |
|---|---|---|---|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics In | -64.6% | 0.23 | 0.66 | 3,188,084 | 86.7% | 15 | Health Technology |
| DRUG | Bright Minds Biosciences I | -45.8% | 29.78 | 54.98 | 11,109 | 8.3% | 542 | Health Technology |
| JAGX | Jaguar Health, Inc. | -36.4% | 1.03 | 1.62 | 563,038 | 12.4% | 4 | Health Technology |
| RCT | RedCloud Holdings plc | -33.3% | 0.04 | 0.06 | 5,934,436 | 16.2% | 4 | Technology Services |
| PGEN | Precigen, Inc. | -28.0% | 5.00 | 6.94 | 819,259 | 16.0% | 2,485 | Health Technology |
| JDZG | JIADE LIMITED | -27.4% | 0.68 | 0.94 | 376,448 | 19.4% | 5 | Commercial Services |
| HUBC | Hub Cyber Security Ltd. | -22.3% | 0.09 | 0.11 | 2,732,615 | 29.1% | 0 | Commercial Services |
| NSSC | NAPCO Security Technologie | -18.2% | 32.20 | 39.35 | 13,549 | 4.5% | 1,407 | Commercial Services |
| FNGR | FingerMotion, Inc. | -15.1% | 0.10 | 0.11 | 1,602,029 | 4.8% | 10 | Technology Services |
| SGRX | SANGRIX INC. | -14.8% | 0.62 | 0.73 | 574,202 | 6.3% | 3 | Consumer Non-Durables |

---

## 5. StockTwits lead read — trending (15)

Every trending row was treated as a price-check trigger and pulled from the screener. Thesis text shown inline.

| # | Ticker | Sector | Trending score | Pre % | Thesis (StockTwits summary) |
|---|---|---|---|---|---|
| 1 | MRVL | ElectronicTechnology | 17.0643 | -3.3% | Marvells all-stock agreement to acquire Lumentum is driving attention, with investors focused on potential shareholder dilution and the deals cost while others see a strategic boost in AI data-center optics and connectivity. The transaction remains subject to shareholder and regulatory approval. |
| 2 | ORCL | TechnologyServices | 17.0322 | -2.9% | Oracles planned bond offering has focused attention on how it will fund its AI data-center expansion, with bears warning about leverage and bulls arguing the borrowing was already part of the disclosed financing plan. The sharp selloff has also fueled debate over whether the market is overreacting a… |
| 3 | LITE | ProducerManufacturing | 16.1847 | -5.1% | Marvells agreed all-stock acquisition of Lumentum is driving attention, with traders debating its strategic fit in AI data-center optics versus concerns about the exchange ratio, dilution, and the long path to closing. Many LITE holders are frustrated that the shares are falling despite the announce… |
| 4 | POET | ProducerManufacturing | 11.9856 | +1.5% | Attention centers on third-party reports that POET optical engines appeared within Foxconns photonics ecosystem at its Tech Day, which bulls view as credibility for the companys AI-optics opportunity. Traders disagree on whether the display signals commercial progress, since it does not confirm prod… |
| 5 | TGTX | HealthTechnology | 10.8528 | +1.3% | Shares have climbed to a fresh 52-week high ahead of Q3 results, with traders citing BRIUMVIs sales growth and the potential of its subcutaneous formulation. Buyout and short-squeeze speculation is prominent, but some investors stress that a deal is unconfirmed and focus instead on earnings and comm… |
| 6 | CRMD | HealthTechnology | 10.5799 | -0.2% | CRMD drew attention after a sharp selloff tied to DaVitas preliminary warning that DefenCath reimbursement could decline through 2027. Traders debate whether the outlook threatens adoption and revenue or is too uncertain to treat as company guidance, with some pointing to CMS reimbursement data and … |
| 7 | AXSM | HealthTechnology | 10.4703 | -3.8% | Axsomes quarterly report showed strong product-revenue growth and a smaller-than-expected loss, with traders highlighting Auvelitys continued sales growth and a possible path toward cash-flow break-even. The reaction is divided: many called the results strong, while others questioned the stocks sell… |
| 8 | AAOI | ElectronicTechnology | 8.61844 | +1.2% | AAOI is drawing attention amid a sharp selloff in AI and optical-infrastructure stocks, with traders debating broader concerns about hyperscaler spending and the companys upcoming earnings. Dip buyers point to data-center optics demand, while bears worry about dilution, cash needs and customer conce… |
| 9 | FLNC | ProducerManufacturing | 8.24702 | -5.5% | Fluences repeated fiscal 2026 guidance cut, attributed mainly to Houston manufacturing delays that are holding up deliveries, is driving bearish attention. Traders question managements execution and whether its backlog can translate into earnings, while some see the steep selloff as a buying opportu… |
| 10 | PGEN | HealthTechnology | 7.71806 | -28.0% | Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about pressure on Precigens PAPZIMEOS. Traders debate whether the rivals dosing approach will erode demand or whether PAPZIMEOSs commercial head start, established payer access and reported sal… |
| 11 | COHR | ElectronicTechnology | 5.86179 | +3.0% | — (no thesis text) |
| 12 | XLV | Miscellaneous | 5.63526 | n/a | — (no thesis text) |
| 13 | CIFR | TechnologyServices | 5.53921 | +0.0% | — (no thesis text) |
| 14 | TEM | TechnologyServices | 4.73691 | +3.9% | — (no thesis text) |
| 15 | CAPR | HealthTechnology | 4.72884 | +6.9% | — (no thesis text) |

- The trending list is **dominated by the Marvell/Lumentum deal and the AI-optics selloff** — MRVL, LITE, POET, AAOI, COHR — plus Oracle's bond question and three biotech names (TGTX, CRMD, AXSM) and FLNC.
- **CRMD is the one trending name with no pre-market follow-through:** it fell 25.5% Friday on DaVitas' preliminary warning that DefenCath reimbursement could decline through 2027, and is now roughly flat pre-market — the selloff has already happened.
- Thesis timestamps: 2026-11-02 13:17–13:23 UTC (08:17–08:23 ET), i.e. pre-market this morning.

## 6. Watchlist

**Not published — the watchlist file is missing in this runtime.** The skill's watchlist (`research/watchlist.yaml`) lives on the local Windows Mavis host; it is not present in the Cloud sandbox and no copy exists in `karizaco/maxhermes-migration` (the repo contains no `.yaml`/`.yml` file at all) or in `karizaco/minimax-cloud-outputs`. Per the skill: no default watchlist was created, and the gap is surfaced in Source health.

---

## 7. Overnight — futures, indices, FX, crypto

| Instrument | Last | vs prior close | As of |
|---|---|---|---|
| ES=F (S&P 500 fut) | 7636.75 | +0.30% | 08:27:48 ET |
| NQ=F (Nasdaq 100 fut) | 28697.0 | +0.57% | 08:27:47 ET |
| YM=F (Dow fut) | 52107.0 | +0.36% | 08:27:47 ET |
| RTY=F (Russell 2000 fut) | 2833.4 | +0.43% | 08:27:47 ET |
| ^VIX | 19.52 | +0.51% | 08:22:46 ET |
| ^TNX (10Y) | 4.908 | -0.43% | 08:22:42 ET |
| DXY | 101.639 | -0.24% | 08:27:49 ET |
| CL=F (WTI) | 99.78 | -4.17% | 08:27:47 ET |
| GC=F (Gold) | 3914.5 | +0.40% | 08:27:49 ET |
| BTC-USD | 77862.99 | -0.48% | 08:37:46 ET |
| ETH-USD | 2290.79 | +0.80% | 08:37:48 ET |

**Europe/Asia:** Nikkei 63,081.86 (-0.33%) · Hang Seng 23,393.32 (+0.42%) · Shanghai Composite 3,638.03 (+1.08%) · FTSE 100 10,712.90 (-0.16%) · DAX 25,796.03 (-0.09%).

**Friday's regular-session close (the backdrop):** SPY 755.72 (-1.77%) · QQQ 690.49 (-3.47%) · IWM 279.33 (-1.65%) · DIA 517.13 (-1.07%) · SMH 522.49 (-6.98%) · XLK 179.51 (-4.89%) · ARKK 80.75 (-6.07%) · XBI 155.98 (-1.15%) · GLD 355.78 (-3.47%) · TLT 81.84 (+0.43%) · XLF 56.51 (-0.76%).

**Read:** futures modestly green after a violent Friday; the 10Y is 2bp lower at 4.908%; VIX at 19.52 is *not* pricing stress. WTI at 99.78 is the outlier (-4.17%).

---

## 8. Macro calendar

| Time (ET) | Release | Period | Previous | Consensus | Forecast |
|---|---|---|---|---|---|
| 09:45 | S&P Global Manufacturing PMI (final) | Oct | 55.9 | 56.0 | 56.0 |
| 10:00 | **ISM Manufacturing PMI** | Oct | 54.5 | 54.6 | 54.7 |
| 10:00 | ISM Manufacturing Employment | Oct | 52.7 | — | 53.0 |
| 10:00 | ISM Manufacturing New Orders | Oct | 55.3 | — | 55.4 |
| 10:00 | ISM Manufacturing Prices | Oct | 77.9 | 77.0 | 78.0 |
| 10:00 | Construction Spending MoM | Sep | 0.9% | 0.4% | 0.2% |

**ISM Prices at 78 with a 10:00 ET print is the one to watch** — after Friday's memory-price-driven semiconductor de-rating, a hot prices sub-index re-prices the PC/consumer-hardware cost story (Intel cited memory costs directly). Note the week is also the **US midterm election week (Nov 3)**.

---

## 9. Earnings today

**Already reported pre-market:** CHH, MAR, FOXA/FOX, ETR, IDXX, PEG, EL, L, TEM, CHKP, CNA, KRYS, AXSM, CIFR, KOS, NSSC. Pre-market reactions observed: **MAR +3.6% ($413.50)** · **FOX +5.0% ($59.00)** · **FOXA +3.9% ($65.70)** · **EL +0.9% ($110.25)** · IDXX +7.8% · TEM +3.9% · AXSM -3.8% · KOS -8.4% · NSSC -18.2% · CHKP -6.0% · CIFR 0.0%.

**After the close:** **AAPL** (Q4 FY26, EPS est $1.98-2.00, rev est $113.46B, $5.03T cap) · **PLTR** (Q3, est $0.40-0.41) · VRTX · WMB · FANG · ON Semiconductor · ROKU · CLX. Also tomorrow (Nov 3): **AMD**, AMGN, ANET.

**Other scheduled today:** BRK.A/BRK-B (Q3) · SHOP · MCD · NVO · QCOM · UBER · PFE · CVS · and ~79-122 reporters in total, depending on the calendar source (Bloomberg 79, askthedate 122, Yahoo 156 incl. unconfirmed slots).

**The catalyst stack is dense tonight: AAPL after the close, into AMD on Nov 3, in the shadow of Friday's AI-capex de-rating and the ISM print.**

---

## 10. Source health

| Source | Query / URL | Status | Result |
|---|---|---|---|
| MCP availability probe | `probe_mcp.py` | ok | `catalog_ok total=133 finance_tools=0` — **no financial MCP registered**; bridge reachable |
| MCP bridge `market-recap` | `get_quotes` (3 batches, 64 symbol requests), `market_snapshot` | ok | Yahoo-sourced closes, futures, FX, crypto; every requested symbol resolved, 0 failures |
| MCP bridge `stocktwits` | `trending_symbols limit=15` | ok | 15 symbols with thesis text |
| TradingView scanner | `POST scanner.tradingview.com/america/scan` | ok | 8 calls: 260-name up-screen, 167-name down-screen, 64 pre-market volume leaders, 30 high regular-session volume, 2 by-symbol checks (15 and 22 tickers requested) |
| MarketChameleon pre-market | via web_search | ok | cross-check at 07:01 ET (INO +235.6%, CLRO +66.6%, PERI +30.8%, PGEN -18.9%) |
| Yahoo Finance (via bridge) | `get_quotes` | ok | no 429 on this egress; Friday closes matched the screener's `close` field on 7/7 spot checks (EVGO, MRVL, LITE, ORCL, PGEN, DRUG, PERI) |
| web_search | 12 searches | ok | MRVL/LITE deal, INO approval, DRUG hold, KPTI Ch.11, EVGO/LS Power, ORCL credit, INTC-Friday, CLRO, macro, earnings |
| SEC EDGAR direct | — | **not attempted** | PERI's 6-K was identified via a secondary source; the filing text was not read |
| **Personal watchlist** | `research/watchlist.yaml` | **failed:not-found** | File exists only on the local Windows host; no copy in either repo → **no watchlist section today** |
| Market-status / cash-open countdown | — | **not attempted** | Open time (09:30 ET) taken from the exchange calendar; no separate status call |

**Degradations:** none of the primary sources failed. Two structural gaps, both disclosed above: the missing watchlist file, and PERI's 6-K content not read at source. Yahoo was reachable on this egress (no 429), so no Yahoo fallback was needed.

---

## 11. Open research queue

1. **PERI's 6-K** — pull the filing text from SEC EDGAR; a +31% move on a 285%-of-ADV print with no readable catalyst is the largest unexplained move on the liquid board.
2. **MRVL/LITE arb** — monitor whether LITE converges to 4.500 x MRVL or the discount persists; the -6.7% gap is the cleanest live read on how the market prices merger risk into a fixed ratio.
3. **EVGO to $2.00** — 9.0% below the LS Power deal price with the vote not done; confirm the special-committee/timeline.
4. **Oracle credit** — watch the 5y CDS and the Nov-2032 note yield (7.24%) for a second-leg widening into the ISM print; this is the channel through which AI-capex stress would spread.
5. **ISM Prices (10:00 ET)** — confirm whether the prices sub-index confirms the memory-cost squeeze that drove Intel's -28.6% and the SOX's -7.2%.

---

_Generated by cron #26 `agentic-pre-market-brief`. Skill: `agentic-pre-market-brief` (market-wide → cluster → watchlist ordering). Read-only by design; no trade actions. Every percentage traces to a fetched value or a cited source._
